IRAZÚ Bio-Holdings
IRAZÚ Bio-Holdings bridges the gap between academic research and drug development by partnering with academic investigators and university centers to accelerate translational research into clinical applications. The company focuses on increasing the value of transformative intellectual property assets and either licenses these to pharmaceutical companies or forms new ventures with VC groups. Their mission is to leverage natural biochemical mechanisms and innovative research to promote survival, prevent disease, and improve quality of life, especially in the context of neuroprotection, immuno-oncology, and gene therapy.
Industries
Nr. of Employees
small (1-50)
IRAZÚ Bio-Holdings
801 W. Baltimore Street, Suite 518, Baltimore, MD 21201
Products
Academic Partnerships
Collaborates with Principal Investigators and university-based Centers of Excellence to accelerate translational research into IND-enabling studies and Phase 1 clinical trials.
Research Curation
Increases value for intellectual property assets through a hands-on approach.
Business Model
Licenses with pharma companies for clinical development of IP assets or starts new companies with venture capital groups.
Hypoxia Tolerance And NeuroProtection
Leverages biochemical mechanisms for potential applications in survival, disease prevention, and life quality improvement in old age.
Immuno-Oncology
Develops 'Bugs as Drugs' for cancer treatment by inducing global immunity targeting unique tumor antigens.
Adeno-Associated Virus (AAV) Gene Therapy
Focuses on gene therapy process development and manufacturing for rare and orphan diseases.
Academic Partnerships
Collaborates with Principal Investigators and university-based Centers of Excellence to accelerate translational research into IND-enabling studies and Phase 1 clinical trials.
Research Curation
Increases value for intellectual property assets through a hands-on approach.
Business Model
Licenses with pharma companies for clinical development of IP assets or starts new companies with venture capital groups.
Hypoxia Tolerance And NeuroProtection
Leverages biochemical mechanisms for potential applications in survival, disease prevention, and life quality improvement in old age.
Immuno-Oncology
Develops 'Bugs as Drugs' for cancer treatment by inducing global immunity targeting unique tumor antigens.
Adeno-Associated Virus (AAV) Gene Therapy
Focuses on gene therapy process development and manufacturing for rare and orphan diseases.
Expertise Areas
- Translational research and clinical acceleration
- IND‑enabling preclinical studies
- Phase I clinical trial support
- Gene therapy process development and manufacturing
Key Technologies
- AAV vector manufacturing
- Gene therapy process development
- Microbial‑based therapeutics ("bugs as drugs")
- Immuno‑oncology platform development
Key People
Lab Manager
Lab Manager
Investors
Seed Round - Irazu Bio
Seed Round - Irazu Bio
News & Updates
Announcement of Isabel Sonam's participation as a speaker at the World Fashion Convention in New York City.
Spencer Ingram featured in an interview with DeCode, discussing relevant topics in design, tech, and venture capital.
Article offering free legal advice for creative professionals, covering art, music, and film.
Bradley Cawthern quoted in an ethics review publication.
Angeline Harris and Spencer Ingram participate as panelists at the Inventor's Symposium, discussing intellectual property.
Article providing legal guidance for creative agencies, authored by Bradley Cawthern.
Announcement of Isabel Sonam's participation as a speaker at the World Fashion Convention in New York City.
Spencer Ingram featured in an interview with DeCode, discussing relevant topics in design, tech, and venture capital.
Article offering free legal advice for creative professionals, covering art, music, and film.
Bradley Cawthern quoted in an ethics review publication.
Angeline Harris and Spencer Ingram participate as panelists at the Inventor's Symposium, discussing intellectual property.
Article providing legal guidance for creative agencies, authored by Bradley Cawthern.